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ABSTRACT
Background
The e2, e3, and e4 alleles of the apolipoprotein E gene (APOE) encode three isoforms, apoE2,
E3, and E4, respectively. The apoE isoforms circulate in different plasma concentrations, but
plasma concentrations of the same isoform also differ between individuals. Whereas the
isoforms have been associated with cardiovascular disease, the relation between plasma apoE
levels and cardiovascular disease is unknown.
Methods and Findings
We assessed APOE genotypes, plasma levels of apoE, cardiovascular risk factors, and mortality
in a population-based sample of 546 individuals aged 85 y who participated in the Leiden 85-
plus Study and were prospectively followed for specific causes of death for 5 y. Participants in
the highest tertile of apoE levels suffered a twofold-increased risk of cardiovascular mortality
(hazard ratio compared to lowest tertile, 2.08; 95% confidence interval [CI], 1.30 to 3.33).
Among the 324 participants with the e3e3 genotype, the hazard from cardiovascular disease
was threefold increased (highest versus lowest tertile 3.01; 95% CI 1.60 to 5.66), with similar
estimates for men and women. Other causes of death were not increased significantly. Plasma
levels of apoE in e3e3 participants were positively correlated with total cholesterol (p , 0.001),
low-density lipoprotein cholesterol (p , 0.001) and triglycerides (p , 0.001) and negatively
with high-density lipoprotein cholesterol levels (p ¼ 0.010). Adjustment for plasma lipids did
not change the hazard ratios, whereas interaction was absent. The risk associated with high
levels of apoE, however, was strongest in participants from the lowest tertile of C-reactive
protein (CRP) levels and absent in those from the highest tertile (pinteraction , 0.001). Among
participants from the lowest tertile of CRP levels, those with a high apoE levels had a
significantly steeper increase in CRP than those with low apoE levels (p ¼ 0.020). Similar
cardiovascular mortality risks as in e3e3 participants were found in e2 and e4 carriers.
Conclusions
In old age, high plasma apoE levels precede an increase of circulating CRP and strongly
associates with cardiovascular mortality, independent of APOE genotype and plasma lipids.
The Editors’ Summary of this article follows the references.
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The apolipoprotein E (APOE) gene inﬂuences lipid metab-
olism and disease risk. The encoded 299-residue plasma
protein apoE is a surface component of primarily triglycer-
ide-rich lipoproteins, such as very low-density lipoproteins
(VLDLs), their remnants, chylomicron remnants, and high-
density lipoproteins (HDLs). ApoE is the main ligand for
clearance of VLDLs and chylomicron remnants, and as such
affects circulating concentrations of lipoproteins and plasma
levels of cholesterol and triglycerides [1].
The biological activity of apoE can be inﬂuenced by
modiﬁcation of its structure and/or quantity. A structural
alteration arises from the two common e2/e3/e4 polymor-
phisms [2], encoding apoE2, apoE3, and apoE4, respectively.
ApoE2 exhibits lower afﬁnity for the LDL receptor, resulting
in slower clearance of apoE and higher plasma apoE levels
[3,4]. In response, the liver up-regulates the LDL receptor,
resulting in lower cholesterol levels. Conversely, apoE4 is
cleared more efﬁciently, resulting in lower apoE levels and
higher cholesterol levels [3,4]. The genetic variations thus
affect lipid metabolism [5] and have been shown to alter risk of
cardiovascular disease [6] and dementia [7]. Plasma apoE levels
are only partially explained by the e2/e3/e4 polymorphism [8],
and plasma apoE levels vary between individuals with the same
APOE genotype. Irrespective of APOE genotype, plasma apoE
levels are also associated with cholesterol levels [9,10]. More-
over, it was shown recently that apoE mediates the presenta-
tion of lipid antigens to the immune system and in this way
inﬂuences the inﬂammatory process [11]. Both lipids and
inﬂammation are involved in the pathogenesis of atheroscle-
rosis, but the relation of plasma apoE levels and cardiovas-
cular disease risk has not yet been reported.
Here, we studied the association of apoE plasma levels with
cardiovascular mortality, independent of APOE genotype. To
this end, within the Leiden 85-plus Study, a population-based
prospective follow-up study, we determined the plasma levels
of apoE, lipids, and C-reactive protein (CRP); APOE e2/e3/e4
genotypes; and mortality from speciﬁc causes in old age.
Methods
Participants
Between 1 September 1997 and 1 September 1 1999, a total
of 705 inhabitants of the community of Leiden, the Nether-
lands, reached the age of 85 y. Among these 85-y-old persons,
we initiated a follow-up study to investigate determinants of
successful aging [12]. There were no selection criteria on
health or demographic characteristics. Fourteen inhabitants
died before they could be enrolled. The response rate was
87%; a total of 599 persons (397 women and 202 men)
participated [13]. There were no signiﬁcant differences in
various demographic characteristics between the 599 re-
spondents and the source population. Of the 599 participants
in the cohort, 38 refused to provide a blood sample, yielding a
total number of 561 participants for the present study. The
Medical Ethical Committee of the Leiden University Medical
Center approved the study, and informed consent was
obtained from all participants.
Cardiovascular Disease History
History of myocardial infarction was obtained from the
participants and from the treating physician. Information on
use of medication was obtained from the participants’
pharmacy records.
APOE Genotypes
For genotyping, two TaqMan assays (Applied Biosystems,
Foster City, California, United States) were used. For the
single nucleotide polymorphism (SNP) in codon 112, primers
were sense 59-GCTGGGCGCGGACAT-39 and antisense 59-
CACCTCGCCGCGGTACT-39, and probes were 59-
CGGCCGCGCACGTCC-39 l a b e l e dw i t hF A Ma n d5 9-
AGGCGGCCGCACACGTC-39 labeled with VIC. For the
SNP in codon 158, an Assay-On-Demand (Applied Biosys-
tems) was used (assay ID C____904973_10). The assays
were run on a 7900HT (Applied Biosystems) according to
manufacturer’s speciﬁcations, with the following modiﬁca-
tions: a Eurogentec qPCR core kit (Eurogentec, Seraing,
Belgium) was used according to standard speciﬁcations; half
the concentrations of primers and probes were used; the
number of PCR cycles was 50. Fluorescence intensities were
measured after the PCR, and genotypes were indicated by the
SequenceDetectionSoftwareversion2.0(AppliedBiosystems).
Plasma Measurements
At baseline, participants were visited twice at their places
of residence within 1 mo after their 85th birthday. All blood
samples were collected early in the morning, although not
fasting. Within the 5 y after inclusion, participants were
visited each year within a month of their birthday. Blood
samples were drawn each year, and CRP and lipid levels were
measured directly in fresh samples as described. ApoE levels
were determined in 2005 in one batch of plasma samples that
were collected at age 85 y at baseline of the study and stored
frozen. Plasma apoE levels were determined using a human
apoE-speciﬁc sandwich ELISA essentially as described [14]; an
afﬁnity-puriﬁed polyclonal sheep antihuman apoE antibody
(ShaE/E, obtained by genetic immunization of sheep followed
by boosting of animals with human apoE) was coated
overnight onto MaxiSorp immune plates (Nunc Intermed,
Roskilde, Denmark) (dilution 1:10
3 in PBS [pH 7.4]; 100 ll/
well) at 4 8C. Plates were washed three times with PBS
containing 0.05% Tween-20 (v/v) (PBS-T), and unspeciﬁc
binding sites were blocked for 1 h at 37 8C with blocking
buffer (PBS containing 0.1% casein). Plates were washed
three times with PBS-T, and 100 lL of the samples, reference
sera (both dilution 1:8,000), and standards (plasma from
C57Bl/6 mice spiked with 0–32 lg/l of human apoE) were
added (all diluted in blocking buffer). The plates were
incubated overnight at 37 8C. Plates were washed ﬁve times
with PBS-T to remove unbound and/or nonspeciﬁcally bound
proteins, and captured antigen was detected by adding 100
lL of horseradish peroxidase (HRP)-conjugated polyclonal
sheep antihuman apoE antibody (dilution 1:10
3 in blocking-
buffer containing 0.05% Tween-20). After a 2 h incubation at
37 8C, plates were washed ﬁve times with PBS-T and 100 ll/
well of freshly prepared tetramethylbenzidine (Organon
Teknika, Boxtel, The Netherlands) was added, and the plates
were put in the dark. After 20 min at room temperature the
product formation was ended by addition of 100 ll/well of 2.5
M sulfuric acid. Following brief mixing, absorbance at 450 nm
was measured. The inter-assay coefﬁcient of variance was
typically less than 10%, while the intra-assay coefﬁcient of
variance was typically less than 4%. Correlation coefﬁcients
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Reagent blanks had a typical absorbance of 0.06 (A450).
Plasma levels of total cholesterol, HDL cholesterol,
triglycerides, and CRP were analyzed on fully automated
computerized analyzers (Hitachi 747 and 911; Hitachi, Tokyo,
Japan). The level of LDL cholesterol was estimated by the
Friedewald equation (LDL cholesterol [mmol/l] ¼ total
cholesterol   HDL cholesterol   [triglycerides/2.2]), whereby
participants with a triglyceride concentration higher than
443 mg/dl (5 mmol/l) were excluded (n ¼ 5).
Other Cardiovascular Risk Factors
Participants were classiﬁed as having diabetes when they
met at least one of the following criteria: (1) history of type 2
diabetes obtained from the general practitioner or treating
physician; (2) use of sulfonylureas, biguanides, or insulin,
based on information obtained from the participant’s
pharmacist; or (3) nonfasting glucose of 11.1 mmol/l or
higher. Participants were classiﬁed as having hypertension
when they met at least one of the following criteria: (1) history
of hypertension obtained from the general practitioner or
treating physician; or (2) mean systolic blood pressure of 165
mmHg or greater, or diastolic blood pressure of 95 mmHg or
greater. Height and weight were measured at baseline, and
body mass index (BMI) was calculated from these measure-
ments. Self-reported history of smoking was categorized in
three categories: never smoked, did smoke but not anymore,
and current smokers.
Causes of Death
For the analyses presented in this research, all participants
were followed for mortality until 1 April 2004. During this
period, of a total of 546 participants, 274 (50%) died. The
date of death was obtained from the civic registries. Shortly
after the civic registries reported the death of a participant,
the general practitioner or nursing home physician was
interviewed to determine the cause of death by means of a
standardized questionnaire. Two senior specialists of internal
medicine, unaware of the outcomes of the analyses, reviewed
the causes of death and classiﬁed each death into primary
causes of death according to the International Classiﬁcation
of Diseases and Related Health Problems, 10th Revision, as
cardiovascular mortality (ICD codes I00–I99), infectious
disease (ICD codes A00–B99 or J11–J18), cancer (ICD codes
C00–D48), or other causes (all other ICD codes). Speciﬁc
causes of death were not available for six participants.
Statistical Analyses
Levels of total, LDL, and HDL cholesterol were normally
distributed. Levels of plasma apoE, triglycerides, and CRP
were not normally distributed, and are reported as geometric
means. To allow transformation, undetectable levels of CRP
were assigned the mean value 0.25. Differences in variables
between groups were compared with a sex-adjusted linear
regression. Sex-adjusted (geometrical) means and 95% con-
ﬁdence intervals (95% CIs), and differences between groups
were calculated using a linear mixed model. Mortality risks
were estimated using Cox proportional hazards model, and
all were adjusted for gender. Prospective analysis of CRP
levels was performed using a linear mixed model, adjusting
for gender. All calculations were performed using SPSS 12.0.1
(SPSS, Chicago, Illinois, United States), and Kaplan-Meier
curves were generated using STATA 8 SE (Stata, College
Station, Texas, United States) and replicated by two
researchers independently (SPM, DvH).
Results
Baseline Study Population Characteristics
From the 561 eligible participants, measurement of plasma
apoE failed in two and APOE genotyping failed in 13. The
remaining 546 participants were included in the present
analysis, of which the baseline characteristics are listed in
Table 1. The APOE allele frequencies in our population were:
e2, 0.10; e3, 0.77; and e4, 0.13. The genotypes were in Hardy-
Weinberg equilibrium and the allele frequencies were in line
with comparable populations [10].
Association of APOE Genotype with Plasma ApoE, CRP,
and Lipid Levels at Baseline and Cardiovascular Mortality
during Follow-Up
When assessing the relation of APOE genotype with plasma
apoE levels, lipids, CRP levels, and cardiovascular mortality
we found associations similar to those already described
[3,4,9,10]. In brief, participants who were carriers of the e2
allele had signiﬁcantly higher plasma levels of apoE and lower
levels of LDL cholesterol and total cholesterol, whereas
carriers of the e4 allele had lower levels of plasma apoE and
higher levels of LDL and total cholesterol (Table 2). Levels of
HDL cholesterol, triglycerides, and circulating CRP did not
differ between the various genotypes. Compared to e3e3
participants, cardiovascular mortality was lower in e2e3 and
e2e4 carriers, and higher in e2e2, e3e4, and e4e4 carriers,
Table 1. Baseline Characteristics of Study Participants
Characteristic Category Value
Total number 546
Sex Female, number (%) 365 (67)
Living status Independent, number (%) 449 (82)
Cardiovascular disease History of myocardial
infarction, number (%)
56 (10)
Use of lipid-lowering
medication, number (%)
6 (1)
Cardiovascular
risk factors
Diabetes mellitus, number (%) 89 (16)
Hypertension, number (%) 255 (53)
History of smoking, number (%) 204 (37)
BMI, mean (SD) 27.2 (4.9)
APOE genotype,
number (%)
e2e2, number (%) 4 (1)
e2e3, number (%) 90 (17)
e2e4, number (%) 13 (2)
e3e3, number (%) 324 (59)
e3e4, number (%) 100 (18)
e4e4, number (%) 15 (3)
Plasma apolipoprotein
levels
ApoE levels, median (IQR), mg/l 50.2 (35.2–72.0)
CRP level Plasma CRP level, median (IQR), mg/l 4.0 (1.0–8.0)
Plasma lipid levels Total cholesterol, mean (SD), mmol/l 5.71 (1.13)
LDL cholesterol, mean (SD), mmol/l 3.68 (0.98)
HDL cholesterol, mean (SD), mmol/l 1.32 (0.40)
Triglycerides, median (IQR), mmol/l 1.33 (1.00–1.95)
IQR, interquartile range; SD, standard deviation.
DOI: 10.1371/journal.pmed.0030176.t001
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possibly due to small numbers.
Association of Plasma ApoE Levels and Mortality during
Follow-Up
Mean follow-up time was 4.2 y. During follow-up, of a total
of 546 participants, 274 (50%) died, of which 115 (42%) died
of cardiovascular causes, 47 (17%) of infectious causes, 44
(16%) of cancer, and 62 (23%) of other causes. In the total
study population, high apoE levels were associated with a
2.08-fold (95% CI, 1.30 to 3.33) increased risk, and inter-
mediate levels with a 1.74-fold (95% CI, 1.09 to 2.79)
increased risk, of cardiovascular mortality compared to those
with low apoE levels (Figure 1). This observation seems to
contradict the associations described above, where the e2e3
genotype was associated with higher levels of apoE, lower
LDL cholesterol, and a lower mortality risk, and e3e4 and e4e4
genotypes had lower levels of apoE, higher LDL cholesterol,
and a higher mortality risk, albeit nonsigniﬁcantly.
To further investigate the effect of plasma apoE levels only
and to eliminate the potentially distorting effect of structural
changes in the apoE proteins, the relations between plasma
levels of apoE and mortality were studied in e3e3 participants
only. First, we assessed whether the effect of levels of apoE was
speciﬁc for cardiovascular mortality as compared with other
causes of death. Estimates of mortality risk dependent on
plasma levels of apoE in e3e3 participants are listed in Table 3.
Participants with high levels of plasma apoE had a twofold
increased all-cause mortality risk (hazard ratio, 2.05; 95% CI,
1.39 to 3.02) as compared to those with low levels. This was
predominantly due to a threefold increase in cardiovascular
mortalityrisk(hazardratio,3.01;95%CI,1.60to5.66),whereas
other causes of death were nonsigniﬁcantly increased. A
similar increase in cardiovascular mortality was found in men
(hazard ratio, 2.89; 95% CI 1.13 to 7.36) and women (hazard
ratio,2.96;95%CI1.27to6.90).Othercausesofdeathwerenot
increased signiﬁcantly. When combined, mortality from all
causes except cardiovascular disease was not signiﬁcantly
increased for participants with intermediate apoE levels
(hazard ratio, 1.19; 95% CI 0.71 to 2.01) and high apoE levels
(hazard ratio, 1.63; 95% CI 0.98 to 2.71), compared to
participants with low levels. Second, we assessed whether the
relation between levels of apoE and cardiovascular mortality
risk was linear. When analyzing cardiovascular mortality risk
over ten strata of plasma apoE level, we observed increasing
cardiovascular mortality associated with increasing plasma
apoE level in a gradual fashion (unpublished data).
Association of Plasma ApoE Levels with Lipid Levels at
Baseline and Relationship of Cardiovascular Mortality Risk
Associated with Plasma ApoE and Lipid Levels
As expected, plasma levels of apoE strongly associated with
levels of LDL and HDL cholesterol and triglycerides (Table 4).
Among e3e3 participants, those with high levels of apoE had
signiﬁcantly higher levels of total cholesterol (p , 0.001), LDL
cholesterol (p , 0.001), and triglycerides (p , 0.001) and
Table 2. Plasma Levels of ApoE, Lipids, CRP, and Cardiovascular Mortality Risk Dependent on APOE Genotype
Category APOE Genotype
e2e2 e2e3 e2e4 e3e3 e3e4 e4e4
Number 4 90 13 324 100 15
ApoE
a, mean (95% CI), mg/l 80.6 (49.0–132) 67.5 *** (61.1–7.52) 64.9 (49.3–85.5) 50.0 (47.2–52.7) 44.1 ** (39.9–48.7) 31.4 *** (24.3–40.6)
Total cholesterol, mean (95% CI), mmol/l 3.91 *** (2.88–4.95) 5.36 *** (5.14–5.58) 5.50 (4.93–6.08) 5.70 (5.59–5.82) 6.15 *** (5.94–6.36) 5.84 (5.31–6.38)
LDL cholesterol, mean (95% CI), mmol/l 2.07 *** (1.17–2.97) 3.23 *** (3.04–3.42) 3.20 (2.68–3.72) 3.70 (3.60–3.80) 4.14 *** (3.96–4.32) 3.77 (3.31–4.24)
HDL cholesterol, mean (95% CI), mmol/l 1.31 (0.92–1.70) 1.36 (1.28–1.44) 1.45 (1.23–1.66) 1.31 (1.27–1.36) 1.27 (1.19–1.35) 1.41 (1.20–1.61)
Triglycerides
a, mean (95% CI), mmol/l 1.16 (0.74–1.82) 1.44 (1.31–1.59) 1.33 (1.04–1.71) 1.38 (1.32–1.45) 1.46 (1.33–1.59) 1.36 (1.08–1.71)
CRP
a, mean (95% CI), mg/l 4.06 (0.97–17.0) 3.46 (2.55–4.67) 2.54 (1.15–5.62) 2.69 (2.30–3.16) 2.73 (2.05–3.64) 2.12 (1.01–4.45)
Cardiovascular mortality, HR (95%CI)
b 2.93 (0.72–12.0) 0.63 (0.35–1.14) 0.77 (0.19–3.15) 1 (ref) 1.36 (0.86–2.13) 2.07 (0.75–5.96)
Mean levels and 95% CIs were sex-adjusted and all participants were aged 85 y. Statistical significance: ** p   0.01; *** p   0.001; for each comparison, the e3e3 genotype served as the
reference group.
aGeometrical mean.
bCardiovascular mortality risk from Cox proportional hazard model adjusted for sex.
DOI: 10.1371/journal.pmed.0030176.t002
Figure 1. Kaplan-Meier Mortality Curve for Tertiles of ApoE Levels
Plasma apoE is indicated at high (red), intermediate (blue) and low
(green) levels, showing that high plasma apoE levels associate with
increased cardiovascular mortality. The p-value indicates the statistical
significance of the association of plasma apoE level with cardiovascular
mortality in a sex-adjusted Cox proportional hazards model.
DOI: 10.1371/journal.pmed.0030176.g001
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ApoE Levels and Cardiovascular Mortalitylower HDL cholesterol (p ¼ 0.010). High levels of HDL
cholesterol associated with decreased cardiovascular mortal-
ity compared to low levels (hazard ratio, 0.58; 95% CI, 0.36 to
0.92). No association was found with cardiovascular mortality
for high levels of LDL cholesterol (hazard ratio, 0.89; 95% CI,
0.58 to 1.39) or triglycerides (hazard ratio, 1.00; 95% CI 0.65–
1.56). To investigate whether the association of apoE levels
with cardiovascular mortality was explained by an adverse
lipid proﬁle, we ﬁrst analyzed the association of apoE with
cardiovascular mortality in strata of low, middle, and high
LDL and HDL cholesterol and triglycerides. We found that
the risk associated with high level of apoE was similar in all
tertiles of LDL and HDL cholesterol and triglycerides. Formal
testing for interactions showed that there was no signiﬁcant
interaction between the risk of cardiovascular mortality
associated with apoE and these lipids (all pinteraction . 0.6).
We then adjusted the mortality analysis for levels of LDL and
HDL cholesterol and triglycerides. Participants with high
levels of apoE had mortality risks similar to those in the crude
model (hazard ratio, 3.09; 95% CI, 1.55 to 6.15). Further
adjustment for the cardiovascular risk factors hypertension,
diabetes, BMI, and smoking did not change the estimate
(hazard ratio, 3.20; 95% CI, 1.56 to 6.59). Finally, we repeated
the cardiovascular mortality analysis within the e3e3 group,
excluding individuals with a positive history of myocardial
infarction (n ¼ 28) and those on lipid-lowering medication (n
¼ 4). In the fully adjusted model the risk associated with high
levels of apoE was 4.14-fold higher than that of participants
with low levels (95% CI, 1.75 to 9.84).
Association of Plasma ApoE Level and Increase in CRP
Level during Follow-Up
We also studied the risk of apoE in strata of CRP, another
cardiovascular risk factor. In the total population, high levels
of CRP are associated with increased cardiovascular mortality
compared to low levels (hazard ratio, 2.42; 95% CI, 1.58 to
3.70). At baseline, e3e3 participants with high levels of apoE
had signiﬁcantly higher levels of CRP than those with
intermediate and low levels (ptrend , 0.001), and adjustment
for sex and lipids did not alter the association (ptrend , 0.001).
The cardiovascular mortality risk associated with high levels
of apoE was dependent on level of CRP (Table 5), as it was
highest in participants with low levels of CRP and absent in
those with high levels of CRP (pinteraction , 0.001). Adjustment
for lipids (pinteraction , 0.001) and other cardiovascular risk
factors (pinteraction , 0.001) did not alter the interaction.
When participants with extreme levels of CRP (. 10 mg/l)
were excluded from the analysis, the results remained similar.
One possible interpretation of this interaction is that high
levels of apoE precede an increase of CRP and in this way
contribute to the pathogenesis of atherosclerosis. To test this
hypothesis we investigated the association of baseline levels of
apoE with levels of CRP during follow-up. We performed this
analysis in the 91 participants in the lowest CRP stratum,
Table 3. Mortality Risk according to Tertiles of Plasma Levels of ApoE in Participants with the e3e3 Genotype
Cause of Death ApoE Plasma Level in e3e3 Participants p-Value for Trend
Low (n ¼ 108) Intermediate (n ¼ 108) High (n ¼ 108)
All causes (n ¼ 159) 1 (ref) 1.47 (0.98–2.19) 2.05 (1.39–3.02) ,0.001
Cardiovascular disease (n ¼ 68) 1 (ref) 2.12 (1.11–4.06) 3.01 (1.60–5.66) 0.001
Infectious disease (n ¼ 27) 1 (ref) 1.36 (0.52–3.55) 1.80 (0.70–4.61) 0.218
Cancer (n ¼ 31) 1 (ref) 2.26 (0.90–5.71) 2.26 (0.87–5.90) 0.095
Other causes (n ¼ 31) 1 (ref) 0.54 (0.21–1.42) 1.21 (0.54–2.70) 0.740
Participants were categorized in tertiles of low, intermediate or high plasma apoE level. Hazard ratios were calculated using a sex-adjusted Cox proportional hazards model for high levels
of apoE compared with low levels of apoE as reference (ref) category. p-Value for trend was calculated with the tertiles as continuous variables into the model. Specific causes of death
were not available for two individuals.
DOI: 10.1371/journal.pmed.0030176.t003
Table 4. Plasma Levels of Total, LDL, and HDL Cholesterol and Triglycerides according to Tertiles Plasma Levels of ApoE in Participants
with the e3e3 Genotype
Plasma Component ApoE Plasma Levels in e3e3 Participants p-Value
for Trend
a
Low (n ¼ 108) Intermediate (n ¼ 108) High (n ¼ 108)
ApoE, mean (95% CI), mg/l
b 29.1 (27.9–30.3) 48.5 (46.5–50.5) 88.1 (84.4–91.9) ND
Total cholesterol, mean (95% CI), mmol/l 5.47 (5.28–5.66) 5.59 (5.41–5.78) 6.05 (5.86–6.24) ,0.001
LDL cholesterol, mean (95% CI), mmol/l 3.51 (3.34–3.68) 3.66 (3.49–3.82) 3.93 (3.76–4.10) 0.001
HDL cholesterol, mean (95% CI), mmol/l 1.39 (1.32–1.46) 1.29 (1.22–1.36) 1.26 (1.19–1.33) 0.010
Triglycerides, mean (95% CI), mmol/l
b 1.16 (1.08–1.25) 1.32 (1.23–1.43) 1.72 (1.60–1.86) ,0.001
Mean levels and 95% CIs of the mean were sex-adjusted. All subjects were aged 85 y.
ap-Value for trend was calculated with the tertiles as continuous variable into the model.
bGeometrical means.
ND, not determined.
DOI: 10.1371/journal.pmed.0030176.t004
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apoE was highest (Table 5). Figure 2 shows the association of
baseline levels of apoE with increases in CRP during follow-
up. We found that high levels of apoE at baseline correlate
with higher increases in levels of CRP during follow-up (p ¼
0.024). Adjusting for classical cardiovascular risk factors did
not change the observed association (p ¼ 0.020). A similar
association was observed in e4 carriers (p ¼ 0.041), but was
absent in e2 carriers (p ¼ 0.76).
Association of Plasma ApoE Levels and Cardiovascular
Mortality in Different APOE Genotypes
To investigate whether the association of plasma apoE with
cardiovascular mortality was also present in carriers of other
genotypes, we repeated the mortality analysis in e2 and e4
carriers separately (Table 6). We found a similar increase in
cardiovascular mortality for participants in the highest apoE
tertile as compared to the lowest tertile in e2 carriers (hazard
ratio, 2.43; 95% CI, 0.44 to 13.5) and e4 carriers (hazard ratio,
4.74; 95% CI, 1.54 to 41.6). When the entire cohort was
analyzed with APOE genotype accounted for, participants
with high levels of apoE had a 3.45-fold increased risk of
cardiovascular mortality (95% CI, 1.98 to 6.02).
Discussion
The main ﬁnding of our study is that in old age, individuals
with high plasma levels of apoE are at an increased risk of
cardiovascular mortality, independent of their APOE geno-
type, lipid levels, and other cardiovascular risk factors. In the
prospective analysis, we also found that high plasma apoE
levels precede a rise in CRP levels. Similar mortality risks
were observed among carriers of the e2o re4 allele.
Plasma ApoE Levels Mark Proatherogenesis
ApoE is often referred to as an antiatherosclerotic protein
(reviewed in [15]). This notion has its basis in observations in
both mice and humans. Mice normally do not develop high
LDL cholesterol levels or atherosclerosis, presumably because
of higher VLDL turnover and the lack of cholesteryl ester
transfer protein. Mice with genetically induced or diet-
induced hyperlipidemia develop accelerated atherosclerosis
that closely resembles all stages of human atherosclerosis, up
to the stage of plaque formation. Although in mice plaque
rupture does not occur and therefore no cardiovascular
events occur, mouse models have proven valuable to study the
biological mechanisms underlying the development of athe-
rosclerosis in humans. In mice, complete knockout of the apoe
gene causes hypercholesterolemia and early atherosclerosis
[16]. Stem cell transplantation that enables these mice to
produce small amounts of murine [17] or human [18] apoE in
macrophages rescues them from atherosclerosis, whereas
mice overexpressing rat apoE have a reduction in plasma
lipoproteins and are resistant to diet-induced hypercholes-
terolemia [19]. In humans, a rare heritable deﬁciency of apoE
also leads to the development of hyperlipoproteinemia and
cardiovascular disease [20]. Within atherosclerotic lesions
macrophages accumulate cholesterol and become foam cells,
which play an important role in the initiation and pro-
Table 5. Cardiovascular Mortality Risk Associated with High Levels of ApoE in Strata of CRP in e3e3 Carriers
ApoE Level Stratum of CRP Level pinteraction-Value
Low (0–1 mg/l) (n ¼ 91) Intermediate (2–5 mg/l) (n ¼ 131) High (.5 mg/l) (n ¼ 102)
Low 1 (ref) 1 (ref) 1 (ref) –
High, crude 3.99 (0.96–16.6) 2.38 (1.02–5.54) 1.16 (0.58–2.30) ,0.001
High, adjusted
a 5.76 (1.20–26.7) 2.10 (0.81–5.45) 1.07 (0.49–2.31) ,0.001
High, adjusted
b 6.08 (0.99–37.3) 2.19 (0.75–6.39) 1.18 (0.50–2.76) ,0.001
Levels of apoE were dichotomized on the median in each stratum of CRP. Number of deaths from cardiovascular cause was ten in low CRP, 24 in intermediate CRP, and 34 in high CRP.
Hazard ratios were calculated using a sex-adjusted Cox proportional hazards model for high levels of apoE compared with low levels of apoE as the reference (ref) category. Interaction
was calculated with apoE and CRP and the interaction term as continuous variables in a Cox proportional hazards model.
aAdjusted for levels of lipids.
bAdjusted for levels of lipids, BMI, history of diabetes, hypertension, and smoking.
DOI: 10.1371/journal.pmed.0030176.t005
Figure 2. High versus Low Levels of Plasma ApoE
High (red) and low (green) levels of the protein are depicted. Plasma
apoE level was dichotomized on the median, showing that participants
with high plasma apoE develop higher CRP levels during follow-up.
Estimates of the geometric mean of circulating CRP levels for all years
were calculated using a sex-adjusted linear mixed model. The p-value
indicates the statistical significance of additional annual increases of CRP
between high and low levels of apoE.
DOI: 10.1371/journal.pmed.0030176.g002
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ApoE Levels and Cardiovascular Mortalitygression of atherosclerosis [15]. ApoE is expressed by macro-
phages in atherosclerotic lesions in vessel walls [21] and up-
regulates cholesterol efﬂux from macrophages [22]. In this
way apoE is involved in decreasing the atherogenic effect of
cholesterol. However, the main portion of the apoE plasma
pool is produced by the liver and only a small fraction by
macrophages [23], and plasma apoE levels are under tight
genetic control [3,24,25]. This contrasts with apoE expression
by macrophages, which is dependent on local factors, such as
cholesterol loading and cytokines [15]. These ﬁndings suggest
that plasma apoE levels may not correlate with macrophage
apoE expression levels. Moreover, the antiatherosclerotic
effect of apoE appears to be speciﬁc for macrophages, as
transplantation of apoE-deﬁcient macrophages into wild-type
mice increases development of atherosclerosis, without
affecting plasma levels of lipids and apoE [26]. Furthermore,
we cannot exclude the possibility that expression of apoE in
other tissues also leads to a reduction in atherosclerosis
[27,28]. These observations suggest that apoE plasma levels
may have little relation to the antiatherosclerotic effect of
apoE in macrophages.
Proposed Mechanisms: Plasma ApoE Levels Associate with
a Detrimental Lipoprotein Profile and/or with a
Proinflammation Response
Here we show that high plasma apoE levels in fact do
associate with an increased cardiovascular mortality risk.
High plasma apoE levels may contribute to cardiovascular
disease via one or both of two two hypothesized mechanisms.
First, high levels of apoE may reﬂect a detrimental lip-
oprotein proﬁle. We speculate that high apoE levels reﬂect
the presence of higher levels of lipoprotein classes such as
small, dense LDL, or VLDL and chylomicron remnants, which
are proatherogenic [29,30]. However, because we found in
our analysis that the effect of apoE on cardiovascular
mortality is independent of lipid levels, the effects of high
apoE may not be mediated by LDL or HDL cholesterol or
triglycerides per se. Levels of triglycerides are closely
correlated with remnant concentrations [31], but did not
associate with cardiovascular disease in our study [12,32].
Furthermore, triglyceride levels do not contribute to the
association of levels of apoE with cardiovascular disease
mortality, as stratiﬁcation and correction for triglyceride
levels did not alter the effect of apoE levels on cardiovascular
disease mortality. Changes in lipoprotein particle sizes have
also been associated with longevity [33], suggesting that the
association of apoE levels with cardiovascular mortality might
be explained by changes in particle sizes. The standard
fractionation method, which was used in the present study, is
unable to distinguish between these subclasses. Alternative
measurements of speciﬁc subclasses may help to elucidate the
underlying detrimental lipid proﬁle. Furthermore, measuring
apoE concentrations in these subclasses could yield insight
into which lipoprotein fraction contributes to the detrimen-
tal effect of high plasma apoE levels, or whether the
detrimental effect of apoE is, for instance, speciﬁc for
HDL-apoE or non-HDL apoE. However, since storage of
plasma samples results in a shift of apoE between the
different lipoproteins [34], and because a large portion of
our study population has died, we are unable to perform such
analysis on this cohort. We suggest that a separate study is
initiated, including fractionation of fresh plasma, and
measuring a series of apolipoproteins, including at least
apoAI, apoB, and apoE within in these subclasses.
The second possible mechanism by which apoE contributes
to cardiovascular disease may be related to the ﬁnding that
apoE has proinﬂammatory properties. Plasma apoE avidly
binds lipid antigens and appears to be critical for the
presentation of lipid antigens by binding to antigen-present-
ing cells through the LDL receptor, which is followed by
endocytosis [11]. The concomitant inﬂammatory response
adequately eliminates the lipid antigen from the circulation.
In this model, high plasma levels of apoE in combination with
increased lipid-antigen presentation lead to chronic inﬂam-
mation and thus may contribute to atherosclerosis. In line
with these experimental data, we now show that high plasma
apoE levels precede chronic inﬂammation (of which circulat-
ing levels of CRP are a marker [35]) and cardiovascular
mortality risk. Taken together, we interpret these ﬁndings to
suggest that, in old age, high plasma apoE levels associate
better with a proinﬂammatory response and/or detrimental
lipoprotein proﬁle than with the antiatherosclerotic effect of
apoE expression in macrophages.
Plasma ApoE Levels Are a Cause, Not a Consequence, of
Atherosclerosis
The association of apoE level and cardiovascular mortality
provides new insight into mechanisms contributing to
Table 6. Cardiovascular Mortality Risk Dependent on Plasma ApoE Level in Subjects with Different APOE Genotypes
Genotype Plasma ApoE Level p-Value
Low Intermediate High
e2 carriers (n ¼ 94) 1 (ref) 0.82 (0.15–4.38) 2.35 (0.44–12.6) 0.314
e3e3( n ¼ 324) 1 (ref) 1.94 (0.96–3.93) 3.20 (1.56–6.59) 0.001
e4 carriers (n ¼ 115) 1 (ref) 2.81 (1.02–7.74) 4.25 (1.38–13.0) 0.009
All (n ¼ 546)
a 1 (ref) 2.10 (1.25–3.53) 3.34 (1.92–5.81) ,0.001
Within each genotype group, subjects were categorized in tertiles of low, intermediate, or high plasma apoE level. For e2 carriers, low is 51 mg/l or lower, and high is 83 mg/l or higher; for
e3e3 carriers, low is 39 mg/l or lower, and high is 61 mg/l or higher; for e4 carriers, low is 33 mg/l or lower, and high is 57 mg/l or higher; for the total cohort, low is 40 mg/l or lower, and
high is 63 mg/l or higher. Number of deaths from cardiovascular causes was 15 in e2 carriers, 68 in e3e3 carriers, 30 in e4 carriers, and 115 in the total population. To allow for comparison
between the effect of the e2 and e4 alleles, e2e4 genotypes were not included in this table. Hazard ratios were calculated with a Cox proportional model for intermediate and high levels of
apoE compared with low levels of apoE as reference (ref) category, adjusted for sex, lipids, BMI, and a history of smoking, diabetes, and hypertension.
aAdditionally adjusted for APOE genotype.
DOI: 10.1371/journal.pmed.0030176.t006
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ated with high levels of apoE was even higher in participants
who did not have a history of myocardial infarction
compared to those who did, high levels of apoE are unlikely
to be the consequence of cardiovascular disease. In our study,
the association of apoE levels with cardiovascular disease was
strongest in participants with low levels of CRP, and in these
persons high levels of apoE preceded an increase in CRP.
However, in participants with high levels of CRP these
associations were not observed. We interpret these results to
indicate that high plasma apoE levels are an early and speciﬁc
indicator of cardiovascular disease risk and drive a proin-
ﬂammatory response. However, once there is a proinﬂamma-
tory state—through whichever mechanism—high plasma
apoE levels do not add to an increased risk. Taken together,
our data may suggest that plasma apoE levels are a causal
factor in cardiovascular mortality risk, and that at least part
of the mechanism involves a proinﬂammatory response.
The observed association of high plasma apoE levels with
increased inﬂammation seems to contradict earlier reports
on speciﬁc anti-inﬂammatory properties of apoE. For
instance, apoE was involved in the direct binding of
lipopolysaccharide, the main toxic component of gram-
negative bacteria [36], thereby decreasing the inﬂammatory
response to lipopolysaccharide [37]. However, the pathways
that neutralize endogenous and exogenous stimuli may be
different. It is logical to assume such a pleiotropic effect,
since genes regulating the inﬂammatory host response are
under balanced evolutionary selection pressure.
Literature Context
In our study population, as in other (younger) populations,
apoE level associates with levels of total cholesterol, HDL
cholesterol, LDL cholesterol, and triglycerides. In youth and
middle age, high LDL cholesterol and low HDL cholesterol
are strong risk factors of cardiovascular disease. In contrast,
in old age, only levels of HDL cholesterol, but not of total
cholesterol, LDL cholesterol, and triglycerides, affect car-
diovascular disease risk [12,32,38,39]. It is tempting to
speculate that a high apoE plasma level is an independent
risk factor of cardiovascular disease in middle age as it is in
old age.
We found, as in other (younger) study populations, that
APOE genotypes associate with plasma levels of apoE. Plasma
apoE levels are highly dependent on heritable factors
[3,24,25], but the APOE e2/e3/e4 genotype is only a minor
determinant of these levels [8,40], and accordingly the
plasma levels of apoE varied markedly in persons with e3e3
genotypes. ApoE2 has lower receptor binding afﬁnity than
apoE3 and apoE4 [41]. ApoE4 binds to lipid particles with
higher afﬁnity than does apoE3 and shows preference for
VLDL, whereas apoE2 and apoE3 mainly bind to HDL [42].
The results of individual studies on the association of the e2
allele and cardiovascular disease have been conﬂicting. Some
studies report signiﬁcant, both harmful and protective
associations, whereas others have reported no associations
[43]. On the other hand, the e4 allele has been associated
with an increased risk of cardiovascular disease in a meta-
analysis of studies up to 1996 [43]. Here we show that the
effect of the plasma levels of apoE masks the effect of the
common APOE e2/e3/e4 genotypes and may explain why the
reported associations of the APOE genotype have been
contradictory; the effect of genotype should be adjusted for
plasma apoE levels.
Strengths and Weaknesses of the Present Study
Blood samples were not drawn fasting, which could add to
the random error of the measurement of triglycerides, apoE,
and CRP. However, all samples were drawn in the early
morning, and the observed associations of APOE genotype
with plasma apoE level, and of apoE plasma level with
triglyceride level, were similar to those found in other studies
using fasting samples, which suggests that the magnitude of
random error is relatively small. The low number of
participants on lipid-lowering medication may result from
the restrictive medication policy by Dutch general practi-
tioners at the time of the enrollment of the Leiden 85-plus
Study (1997–1999). This restrictive policy has been one of the
motivations to initiate a clinical trial. The PROSPER study, in
part carried out in the same region as the current study,
showed that lipid-lowering medication (in this case pravasta-
tin) protects individuals from coronary artery disease at least
up to the age of 82 [38]. However, the results of this study
were published several years after the start of the Leiden 85-
plus Study (2003). CRP levels were not measured with high-
sensitivity methods. The use of high-sensitivity CRP measure-
ment is especially informative in discriminating between
samples with none or very little CRP. However, in this age
group the number of participants with levels of CRP below
the detection limit of the assay was relatively small (102 out of
563 participants), and the variation in CRP levels was
considerable. Furthermore, most of the analyses performed
with these CRP levels involved stratiﬁcation for CRP, and it is
unlikely that high-sensitivity measurements would have
systematically changed the attrition of participants to these
strata. Therefore we believe that the measurement that we
used resulted in adequate discriminative power.
A limitation of our study is that this ﬁnding cannot directly
be extrapolated to the incidence of nonfatal cardiovascular
disease, and not beyond this age group. The current study was
performed in a population-based sample of 85-y-olds. The
participants of this study were the survivors of their birth
cohort, and earlier studies in people of over 70 y of age have
shown that biology in old age may be different from that in
other age groups, which may prevent extrapolation of the
results to the population at large. For instance, LDL
cholesterol is no longer a cardiovascular risk factor [38].
Reaching the age of 85 y is becoming less unusual than is
generally expected. The proportion of the original birth
cohort that has reached this age is 36% for women and 15%
for men, and this proportion will further increase in the
future. Furthermore, to our knowledge we are the ﬁrst to
report an association of plasma apoE levels with cardiovas-
cular mortality in any age group, and it is tempting to
speculate that this ﬁnding holds in other age groups. A
strength of our study is the speciﬁcity and sensitivity of the
analyses due to the high incidence of fatal events during
follow-up. Moreover, the data come from a population-based
study without inclusion criteria based on health and
demographic characteristics. Another strong point is that
we could restrict our analyses to APOE e3e3 carriers, thereby
eliminating the potentially distorting effect of structural
changes in the apoE protein.
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ApoE Levels and Cardiovascular MortalityGeneral Conclusion
The present data show that a high apoE plasma level is a
new predictor of cardiovascular mortality in elderly people.
We conclude that levels of apoE may indicate a detrimental
lipoprotein proﬁle and/or a proinﬂammatory response, which
both contribute to cardiovascular mortality.
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ApoE Levels and Cardiovascular MortalityEditors’ Summary
Background. Atherosclerosis is a common disorder of the blood vessels.
Blood lipids (fatty substances, for example cholesterol and other
substances collect on the inner walls of the vessels and form layers,
known as plaques. Eventually, these plaques can interfere with blood
flow though the blood vessels. They can also break apart, causing debris
to travel through the bloodstream to other parts of the body and block
vessels there. This rupture is a common cause of heart attack and stroke.
Scientists believe that inflammation (that is, activation of the body’s
immune system) helps cause atherosclerosis. ApoE is a protein present in
the blood that influences how cholesterol and other fats are made and
removed from the body. ApoE can also have an effect on inflammation.
Different people have different levels of apoE in their blood, depending
on which version of the APOE gene (which codes for the apoE protein)
they have as well as other factors.
Why Was This Study Done? Knowing that apoE can influence both
blood lipid levels and inflammation, and that the specific version of the
APOE gene can affect a person’s risk for cardiovascular disease, this study
was designed to test whether blood levels of apoE can then affect the
risk of death from cardiovascular disease (such as heart attack and
stroke).
What Did the Researchers Do and Find? They studied 546 patients
who were 85 years and older. All patients gave blood samples within a
month after their 85
th birthday and then every following year within a
month of their birthday. Within the five years of the study, 274
participants died, 115 of them from cardiovascular disease. The
researchers analyzed the blood samples in the following ways. They
measured apoE protein levels in the first blood sample and also
determined the variants of the APOE gene for each participant. For the
first and all following yearly blood samples, they also measured
cholesterol, other lipids, and a substance called CRP. CRP is a marker
of inflammation and known to be raised in patients with cardiovascular
disease. The researchers found that in these patients, those who had
high levels of apoE at age 85 had a higher risk of later death from
cardiovascular disease. This higher risk was independent of which
version of the APOE gene the patients had. It was also independent of
their lipid levels and other known risk factors such as smoking and
diabetes. The strongest relationship between apoE levels and cardio-
vascular mortality was seen in patients who had low CRP levels at age 85.
In most of these patients, CRP levels rose in the following years,
suggesting that high apoE levels come before an increase in
inflammation.
What Do These Findings Mean? In old age, at least, high apoE
concentrations in the blood indicate an increased risk of death from
cardiovascular disease. The results suggest that the common assumption
that apoE has antiatherosclerotic effects and therefore protects against
cardiovascular disease is too simple. ApoE levels in the blood might have
different effects than apoE in specialized immune cells called macro-
phages that are involved in atherosclerosis. Only six of the 546
participants were taking lipid-lowering drugs such as statins. This is a
much smaller percentage than would be expected under current
recommendations in the US and Europe. It is not clear whether the
same results would have been found if more of the patients had been
taking other lipid-lowering drugs, so more research is needed to study
whether the observed relationship also holds for persons on lipid-
lowering medication.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030176.
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